OBJECTIVE: Investigate if multifocal papillary thyroid microcarcinoma (PTM) increases the risk of cancer in the contralateral thyroid lobe, thereby warranting a completion thyroidectomy for treatment. METHOD: A retrospective analysis of all newly diagnosed PTM patients presenting to a tertiary care center between 1998-2008. Patients underwent a total thyroidectomy with a minimum follow-up of 1 year. Pathology specimens were evaluated by a single pathologist, and patients were grouped as unifocal or multifocal PTM. The primary outcome variable was PTM in both thyroid lobes; disease recurrence was a secondary outcome variable. Dependent variables included age, gender, tumor size, and focality. Fishers exact test was used to investigate the risk of contralateral thyroid lobe spread in the setting of unifocal versus multifocal PTM. RESULTS: 39 of 67 (58%) PTM patients met eligibility. 11 of 39 (28%) patients had multifocal PTM and 28 of 39 (72%) unifocal PTM diagnosed on initial lobectomy. There were no statistically significant differences in age, gender, and tumor size between the groups. Bilateral thyroid lobe PTM occurred significantly more often in the multifocal group (4/11, 36.4%) than unifocal group (1/28 cases, 3.6%), pϭ0.017. The relative risk of a multifocal PTM patient harboring cancer in both thyroid lobes was 10.09 times that of unifocal counterparts. At a median follow-up of 26 months there were no recurrences. CONCLUSION: Multifocal PTM is 10 times more likely to involve both thyroid lobes at the time of diagnosis compared to unifocal PTM. This increased risk justifies offering a patient with multifocal PTM a completion thyroidectomy. Interventions: none (observational study). Outcome Measures: (Part 1) Incidence of disease recurrence, if any, and its temporal significance; the relationship between recurrence and patient-reported symptoms versus physician suspicion at routine follow-up; (Part 2) Outcomes of patient survey. Independent variables: Patient demography, original cancer stage, cancer type, treatment received and established follow-up plan. Statistical Methods: Data were analyzed using SPSS for Windows statistical package (SPSS Inc., Chicago, IL). Part 1 data were subjected to sensitivity and specificity testing.
Analysis of Head and Neck Cancer Patient Follow-Up Regimes

RESULTS:
The case mix was representative of all head and neck tumor sites and stages. Suspicion of recurrence was noted in 10% (nϭ96/951) of patients seen routinely. This rose to 68% (nϭ60/88) for the subset of patients who had requested an appointment. Most recurrences were found within the first follow-up year. Only 0.3% (nϭ3/1039) of asymptomatic patients attending routine appointments were suspected of having a recurrence, of whom 2 (0.2%) were found to have an actual recurrence following investigation. Of the total number of patients reporting a new symptom, recurrence was suspected in 56% (nϭ152/270). Patients thus had 98.1% sensitivity to raising suspicion for a recurrence based on the reporting of new symptoms with a 99.6% negative predictive value. CONCLUSION: Our data shows that the efficiency of the current system of routine follow-ups at detecting suspected recurrence of head and neck cancer is 10%, suggesting the need for a customized, more focused follow-up regime, tailored to individual cases. Patient education and close relationships with clinicians and allied health-care professionals are essential for early diagnosis and management of cancer recurrence. Follow-up within the first year should be most intensive as recurrence is most likely within this time, and it serves to alleviate patient anxiety in the early post-treatment period.
Cetuximab Therapy for Head and Neck Cancer: A Meta-Analysis
M Boyd Gillespie, MD (presenter); Travis Reeves, MD; Shaun Nguyen, MD, MA OBJECTIVE: To investigate the effectiveness and safety of cetuximab in the treatment of advanced HNSCC by a critical literature review and meta-analysis. METHOD: Two independent searches of PubMed 1966present were performed to identify clinical trials of cetuximab for HNSCC. Study outcomes of interest included treatment response, rate of grade three and four toxicities, and overall survival. RESULTS: Thirteen studies met the inclusion criteria. Heterogeneity in study design, study outcomes, patient populations, and treatment prevented a traditional meta-analysis. Eight phase I or II single-arm clinical trials of cetuximab alone or in combination with platinum-based therapy for recurrent and/or metastatic HNSCC demonstrated a complete response rate of 7% (95% C.I., 4.8-9.1%), a partial response rate of 20.4% (95% C.I., 17.0-23.0%), a grade three or four toxicity rate of 40.1% (95% C.I., 34.9-45.3%), and a median survival of 216 days. Two phase III randomized, controlled trials of cetuximab with platinum for recurrent and/or metastatic HNSCC showed a 38% (95% C.I., 35-39%) survival advantage over platinumbased therapy alone at 1 year but a 60% increase in grade three or four toxicity. Three clinical trials of cetuximab with radiation therapy with or without platinum for locally advanced, untreated HNSCC observed a two-year survival rate of 63% (95% C.I., 57.7-69.7%).
CONCLUSION:
Cetuximab with or without platinum appears to be an effective therapeutic alternative for recurrent or metastatic HNSCC, although the toxicity is higher than platinumbased therapy alone. Further studies are needed to determine whether cetuximab provides added benefit at acceptable toxicity compared to current chemoradiation protocols.
Curcumin Inhibits Skin Squamous Cell Carcinoma Tumor Growth
Jeffrey Phillips, MD, MS (presenter); Cheryl Clark, PhD; Lilantha Herman Ferdinandez, MD, DO; John Clifford, PhD; Cherie-Ann Nathan, MD OBJECTIVE: Squamous cell carcinoma (SCCa) has increased from 4-10% over four decades, stimulating interest in developing novel agents that slow sun-damaged skin progression. This is the first study evaluating the naturally-occurring bioactive food compound curcumin on skin cancer xenografts. Low bioavailability of curcumin has slowed its transition to clinical trials. We hypothesize curcumin has growth inhibitory effects through the MTOR pathway and great chemopreventive potential in skin SCCa where local application could bypass bioavailability problems. METHOD: SCID mice were pre-treated with 0, 5, or 15mg of curcumin (nϭ8/group), 3 days prior to injecting 106 SRB12-p9 skin SCCa cells in each flank, and gavaged daily thereafter. Tumor volumes were measured and tumors harvested on day 24 when mice were sacrificed. Western blot analysis of pS6 expression (nϭ3/group) and tumor volumes in the 3 groups were compared using one-way ANOVA, and pairwise comparisons determined with Tukey's t-values test if overall comparisons were significant. RESULTS: Tumor volume increased 2.3 times faster in control mice compared to 15mg curcumin (pϭ0.0003). A significant difference in average tumor volumes was seen (pϭ0.0012), especially with treatment of 15mg curcumin compared to control group (pϭ0.0003). Curcumin inhibited S6 phosphorylation (pϭ0.0027), indicating MTOR pathway inhibition. CONCLUSION: This is the first curcumin skin SCCa xenograft study. Curcumin appears to inhibit skin SCCa growth and blocks tumor progression by inhibiting pS6 even when gavage was used to deliver curcumin indicating even more significant effects in future experiments with local application.
Does Diameter Matter? TEP Diameter and Complications
Heather Starmer, MA (presenter); Christine Gourin, MD; Jeremy Richmon, MD; Nishant Agrawal, MD; Wayne Koch, MD OBJECTIVE: 1) Determine if larger diameter prostheses carry greater risk of prosthesis-related complications. 2) Explore
